Supernus Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Supernus Pharma (SUPN) Tops Q3 EPS by 44c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
November 3, 2020 4:33 PM ESTSupernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.74, $0.44 better than the analyst estimate of $0.30. Revenue for the quarter came in at $155.1 million versus the consensus estimate of $130.66 million.
Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 millionQ3 2020... More